<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523939</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00009742</org_study_id>
    <nct_id>NCT00523939</nct_id>
  </id_info>
  <brief_title>DepoCyt for Active Lymphomatous or Leukemic Meningitis</brief_title>
  <official_title>Phase II Study of Intrathecal Therapy With DepoCyt for Active Lymphomatous or Leukemic Meningitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Enzon Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the response rate of lymphomatous meningitis or
      leukemic meningitis to DepoCyt. The safety of DepoCyt, the number of people who respond well
      to the study drug, and the response of symptoms to the study drug will also be determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DepoCyt is a sustained-release formulation of the chemotherapy drug, cytarabine (Ara-C),
      which is used for the treatment of patients with lymphomatous or leukemic meningitis, a
      complication of lymphoma/leukemia that is characterized by the spread of cancer to the
      central nervous system.

      DepoCyt is introduced into the spinal fluid, through a needle inserted into the spinal canal
      or through a reservoir placed under the scalp by a neurosurgeon. DepoCyt will be given every
      two weeks i.e. week 1 and week 3 initially. After the second dose, a lumbar puncture will be
      done to check the spinal fluid for cancer cells. If there has been a good response, DepoCyt
      will be given every 14 days for 6 doses i.e., weeks 5, 7, 9, 11, 13, 15 and then every 28
      days for six doses i.e., weeks 19, 23, 27, 31, 35, and 39. Blood tests and lumbar punctures
      will be done throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual.
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate response rate using intrathecal DepoCytTM in two cohorts of patients, one with active lymphomatous meningitis and another with active leukemic meningitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Neurologic Progression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Neoplastic Meningitis</condition>
  <condition>Lymphoma, B Cell</condition>
  <arm_group>
    <arm_group_label>Lymphomatous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Lymphomatous Meningitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leukemic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Leukemic Meningitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine liposome injection</intervention_name>
    <description>50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses</description>
    <arm_group_label>Lymphomatous</arm_group_label>
    <arm_group_label>Leukemic</arm_group_label>
    <other_name>DepoCyt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologically confirmed, or radiographic evidence for lymphomatous or leukemic
             meningitis. If the CSF cytology is negative, patients must have MRI/CT brain and
             clinical findings consistent with neoplastic meningitis.

          -  Karnofsky Performance Score of 60 or above.

          -  Age ≥ 18 years.

          -  Patients must have adequate hematologic, renal and liver function. Laboratory

          -  Absolute neutrophil count (ANC) ≥ 1,500/mm3 or white blood cell count &gt; 3,000/mm3

          -  Platelet count ≥ 100, 000/mm3

          -  BUN and serum creatinine must be ≤ 1.5 times upper limit of laboratory normal

          -  Total and direct serum bilirubin must be ≤ 1.5 times upper limit of laboratory normal

          -  SGOT and SGPT ≤ 3.0 times upper limit of laboratory normal

          -  Alkaline phosphatase derived from liver ≤ 2.0 times upper limit of laboratory normal

          -  No uncontrolled infection other than human immunodeficiency virus that is being
             treated with anti-retroviral therapy

          -  Patients who have had prior CNS radiation, prior intrathecal methotrexate, and prior
             CNS prophylaxis with intrathecal or intravenous cytarabine or methotrexate are
             eligible

          -  Written informed consent

        Exclusion Criteria:

          -  Experimental/Investigational chemotherapy, immunotherapy, or biologic therapy within
             four weeks prior to study

          -  Concurrent systemic chemotherapy with high dose methotrexate, high dose cytarabine, or
             high dose thiotepa (they cross the blood brain barrier at high levels)

          -  Patients receiving whole brain radiotherapy or craniospinal irradiation

          -  Previous (less than 2 years from diagnosis) or concurrent malignancies at other sites
             with the exception of fully treated carcinoma in situ of the cervix, basal cell
             carcinoma of the skin, and squamous cell carcinoma of the skin, or prostate cancer not
             requiring ongoing chemotherapy

          -  Pregnant or lactating women

          -  Known active meningeal infection

          -  Evidence of obstructive hydrocephalus requiring neurosurgical intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Rizzieri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <results_first_submitted>February 16, 2011</results_first_submitted>
  <results_first_submitted_qc>February 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2011</results_first_posted>
  <last_update_submitted>June 7, 2013</last_update_submitted>
  <last_update_submitted_qc>June 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Leukemic Meningitis</keyword>
  <keyword>Lymphomatous Meningitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment June 2006 - September 2008. Study stopped early due to poor accrual.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lymphomatous</title>
          <description>Subjects with Lymphomatous Meningitis</description>
        </group>
        <group group_id="P2">
          <title>Leukemic</title>
          <description>Subjects with Leukemic Meningitis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lymphomatous</title>
          <description>Subjects with Lymphomatous Meningitis</description>
        </group>
        <group group_id="B2">
          <title>Leukemic</title>
          <description>Subjects with Leukemic Meningitis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>To evaluate response rate using intrathecal DepoCytTM in two cohorts of patients, one with active lymphomatous meningitis and another with active leukemic meningitis.</description>
        <time_frame>1 year</time_frame>
        <population>Primary outcome measure was not assessed due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Lymphomatous</title>
            <description>Subjects with Lymphomatous Meningitis</description>
          </group>
          <group group_id="O2">
            <title>Leukemic</title>
            <description>Subjects with Leukemic Meningitis</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>To evaluate response rate using intrathecal DepoCytTM in two cohorts of patients, one with active lymphomatous meningitis and another with active leukemic meningitis.</description>
          <population>Primary outcome measure was not assessed due to early study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Neurologic Progression</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lymphomatous</title>
            <description>Subjects with Lymphomatous Meningitis</description>
          </group>
          <group group_id="O2">
            <title>Leukemic</title>
            <description>Subjects with Leukemic Meningitis</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Neurologic Progression</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>Subjects with Lymphomatous or Leukemic Meningitis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term, disease progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Arachnoiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <description>Thrombocytopenia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Slurred speech</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Acanthoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <description>Possible seizure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Folliculitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DVT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Adverse events for both arms, lymphomatous and leukemic, were combined due to low accrual and early study termination.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. David Rizzieri</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-668-1040</phone>
      <email>rizzi003@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

